{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:11:23Z","timestamp":1788952283850,"version":"build-2803163510"},"reference-count":334,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jconrel.2021.12.009","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T11:41:17Z","timestamp":1639222877000},"page":"782-811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies"],"prefix":"10.1016","volume":"341","author":[{"given":"Honey","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinni","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Kumar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Tiwary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2021.12.009_bb0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ana.24897","article-title":"The burden of neurological disease in the United States: A summary report and call to action","volume":"81","author":"Gooch","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","article-title":"Burden of neurological disorders across the US from 1990-2017: a global burden of disease study","volume":"78","author":"Feigin","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0015","doi-asserted-by":"crossref","first-page":"15434","DOI":"10.1039\/C7NR05216B","article-title":"Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles","volume":"9","author":"Rehman","year":"2017","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2019.02.012","article-title":"Chitosan and chitosan coating nanoparticles for the treatment of brain disease","volume":"560","author":"Yu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.trci.2017.10.005","article-title":"Drug discovery and development: Role of basic biological research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0030","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.2174\/1381612823666170913164738","article-title":"The transport mechanism of extracellular vesicles at the blood brain barrier","volume":"23","author":"Matsumoto","year":"2017","journal-title":"Curr. Pharm. Design"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1567201814666171013150534","article-title":"Nanomedicine for intranasal delivery to improve brain uptake","volume":"15","author":"Patel","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0040","first-page":"1","article-title":"Mechanistic comparison of current pharmacological treatments and novel phytochemicals to target amyloid peptides in Alzheimer\u2019s and neurodegenerative diseases","volume":"6","author":"Ayyalasomayajula","year":"2017","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/0929867324666171026163144","article-title":"Peptides and their metal complexes in neurodegenerative diseases: from structural studies to nanomedicine prospects","volume":"25","author":"Trapani","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0050","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.biomaterials.2012.10.013","article-title":"Synthesis of TAT-peptide tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases","volume":"34","author":"Malhotra","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0246007","article-title":"Prediction of nasal spray drug absorption influenced by mucociliary clearance","volume":"16","author":"Shang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0065","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3389\/fnins.2020.00494","article-title":"Nanotechnology: A promising approach for delivery of neuroprotective drugs","volume":"14","author":"Naqvi","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0070","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","article-title":"Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery","volume":"10","author":"Krishna","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120351","article-title":"Evolving new-age strategies to transport therapeutics across the blood-brain-barrier","volume":"599","author":"Choudhari","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2020.02.020","article-title":"Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting","volume":"321","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-9798-5_15","article-title":"Lipid nanocarriers for enhanced delivery of temozolomide to the brain","volume":"2059","author":"Khosa","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0090","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s13346-019-00679-2","article-title":"Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme","volume":"10","author":"Jena","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0095","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3389\/fimmu.2017.01181","article-title":"Targeting malignant brain tumors with antibodies","volume":"8","author":"Razpotnik","year":"2017","journal-title":"Front.Immunol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0100","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/cancers12010175","article-title":"Polymeric nanoparticles for the treatment of malignant gliomas","volume":"12","author":"Mahmoud","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0110","first-page":"185","article-title":"Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook","volume":"25","author":"Sabir","year":"2020","journal-title":"Drug Discov."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/21691401.2016.1167703","article-title":"Ropinirole-dextran sulfatenanoplex for nasal administration against Parkinson's disease: in silico molecular modeling and in vitro-ex vivo evaluation","volume":"45","author":"Pardeshi","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/mp.2015.166","article-title":"The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders","volume":"21","author":"Quintana","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0125","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/pharmaceutics11110598","article-title":"Perivascular and perineural pathways involved in brain delivery and distribution of drugs after intranasal administration","volume":"11","author":"Lochhead","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ar.23816","article-title":"Cranial pair I: the olfactory nerve","volume":"302","author":"Crespo","year":"2019","journal-title":"Anat. Rec."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0135","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/molecules25081929","article-title":"Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders","volume":"25","author":"Islam","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0140","first-page":"1","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development.","author":"Keller","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4614-7978-9_5","article-title":"Considerations for the development of nasal dosage forms","volume":"6","author":"Ehrick","year":"2013","journal-title":"Sterile Prod. Dev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0150","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/10717544.2014.920431","article-title":"Nasal-nanotechnology: revolution for efficient therapeutics delivery","volume":"23","author":"Kumar","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(99)00442-1","article-title":"Determination of baseline human nasal pH and the effect of intranasally administered buffers","volume":"198","author":"Washington","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10611860903055470","article-title":"Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium","volume":"17","author":"Mistry","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","article-title":"Effects of physicochemical properties and other factors on systemic nasal drug delivery","volume":"29","author":"Romeo","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresbull.2020.04.012","article-title":"Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats","volume":"160","author":"Bors","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-017-0908-0","article-title":"Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study","volume":"17","author":"Santos-Morales","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0180","article-title":"Placebo\/active controlled, safety, pharmaco-kinetic\/dynamic study of INP105 (POD\u00ae olanzapine) in healthy adults","volume":"20","author":"Shrewsbury","year":"2019","journal-title":"West. J. Emerg. Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/01926230600713475","article-title":"The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium","volume":"3","author":"Harkema","year":"2006","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0190","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/jam.2006.19.92","article-title":"Nasal clearance in health and disease","volume":"19","author":"Illum","year":"2006","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","article-title":"Barrier properties of mucus","volume":"61","author":"Cone","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0205","series-title":"Nanoparticles Lung - Environ. Exp, Drug Deliv","first-page":"1","article-title":"Potential for nose-to-brain delivery of drugs","author":"Illum","year":"2014"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0215","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: Mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0220","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/jpet.108.145565","article-title":"Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system","volume":"328","author":"Dhuria","year":"2009","journal-title":"J. Pharmacol. Exper. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1164\/rccm.201804-0734OC","article-title":"Localization of secretory mucins MUC5AC and MUC5B in normal\/healthy human airways","volume":"199","author":"Okuda","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"b14","key":"10.1016\/j.jconrel.2021.12.009_bb0235","first-page":"00398","article-title":"The effect of cilia and the mucociliary clearance on successful drug delivery","author":"Gizurarson","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","volume":"570","author":"Martins","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.09.023","article-title":"The biology of mucus: Composition, synthesis and organization","volume":"124","author":"Bansil","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0250","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1021\/acs.jmedchem.9b02001","article-title":"EGF containing membrane bound mucins: A hidden ErbB2 targeting pathway","volume":"63","author":"Liberelle","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0255","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration","volume":"152","author":"Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0260","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.ymthe.2018.07.018","article-title":"Post-injury nose-to-brain delivery of Activin A and SerpinB2 reduces brain damage in a mouse stroke model","volume":"26","author":"Buchthal","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0270","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2006.09.015","article-title":"Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin","volume":"116","author":"Yin","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0275","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/17425247.2019.1684895","article-title":"Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment","volume":"16","author":"Rehman","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/chemse\/bjr063","article-title":"Aquaporin pathways and mucin secretion of bowman\u2019s glands might protect the olfactory mucosa","volume":"37","author":"Solbu","year":"2012","journal-title":"Chem. Senses"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0285","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00414-012-0682-x","article-title":"Nasal ciliary motility: A new tool in estimating the time of death","volume":"126","author":"Romanelli","year":"2012","journal-title":"Int. J. Legal Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4155\/tde.11.149","article-title":"Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective","volume":"3","author":"Landis","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0300","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4168\/aair.2019.11.3.306","article-title":"Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency","volume":"11","author":"Jiao","year":"2019","journal-title":"Allergy Asthma Immunol. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2017.1390","article-title":"Pulmonary toxicity of benzalkonium chloride","volume":"31","author":"Johnson","year":"2018","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0310","series-title":"Sterile Product Development","first-page":"99","article-title":"Considerations for the development of nasal dosage forms","author":"Ehrick","year":"2013"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0315","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1021\/es800720n","article-title":"Influence of size, shape, and flexibility on bacterial passage through micropore membrane filters","volume":"42","author":"Wang","year":"2008","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0320","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40199-019-00316-w","article-title":"Review of recently used techniques and materials to improve the efficiency of orally administered proteins\/peptides","volume":"28","author":"Ibrahim","year":"2020","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0325","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/jphp.12749","article-title":"Modulating nasal mucosal permeation using metabolic saturation and enzyme inhibition techniques","volume":"69","author":"Dhamankar","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0330","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0335","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2217\/nnm.13.178","article-title":"Strategies for improving mucosal drug delivery","volume":"8","author":"Laffleur","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020039","article-title":"Nose-to-brain delivery of antiviral drugs: a way to overcome their active efflux","volume":"10","author":"Dalpiaz","year":"2018","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0345","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/1389200217666160406120509","article-title":"Drug-metabolizing enzymes and efflux transporters in nasal epithelium: Influence on the bioavailability of intranasally administered drugs","volume":"17","author":"Oliveira","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/484963","article-title":"Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy","author":"Hoosain","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0355","first-page":"2841","article-title":"Effect of N-acetyl-L-cysteine on bioavailability and brain distribution of curcumin by nasal delivery","volume":"44","author":"Su","year":"2019","journal-title":"Zhongguo Zhong Yao Za Zhi."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0360","first-page":"497","article-title":"Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain- current development","volume":"11","author":"Wen","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0365","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0370","unstructured":"I.W. Frey, L.R. Hanson, S.V. Dhuria, Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system, U.S. Patent 9,808,509, (2017)."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0375","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.3390\/ijms20153646","article-title":"Therapeutic use of intranasal glucagon: resolution of hypoglycemia","volume":"20","author":"Pontiroli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0380","article-title":"Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations","volume":"388","author":"Yeomans","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0385","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/s41467-020-14845-5","article-title":"Paloyelis effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans","volume":"11","author":"Martins","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108561","article-title":"Intranasal vasopressin modulates resting state brain activity across multiple neural systems: evidence from a brain imaging machine learning study","volume":"190","author":"Chen","year":"2021","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0400","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4193\/Rhino16.054","article-title":"Intranasal sodium citrate solution improves olfaction in post-viral hyposmia","volume":"54","author":"Whitcroft","year":"2016","journal-title":"Rhinol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0405","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0410","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0415","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0420","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40005-020-00482-z","article-title":"Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays","volume":"50","author":"Gao","year":"2020","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0425","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13287-021-02274-0","article-title":"Advances in intranasal application of stem cells in the treatment of central nervous system diseases","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2021.105757","article-title":"Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake","volume":"155","author":"Chari","year":"2021","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0435","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/epi.16449","article-title":"Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers","volume":"61","author":"Hogan","year":"2020","journal-title":"Epilepsia."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0440","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fnins.2018.00215","article-title":"Insulin resistance as a therapeutic target in the treatment of alzheimer's Disease: a state-of-the-art review","volume":"12","author":"Benedict","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0258-6","article-title":"The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer\u2019s pathology","volume":"9","author":"Westwood","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0450","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1084\/jem.20160493","article-title":"Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence","volume":"213","author":"Stanley","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0455","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: a transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0460","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal treatment of central nervous system dysfunction in humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0465","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and alzheimer's disease biomarkers: a pilot clinical trial","volume":"57","author":"Craft","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0470","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/mp.2016.234","article-title":"Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial","volume":"22","author":"Hamidovic","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(03)00341-7","article-title":"Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats","volume":"263","author":"Wang","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40824-020-0184-8","article-title":"Emerging role of nanosuspensions in drug delivery systems","volume":"24","author":"Jacob","year":"2020","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0485","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nano.2016.08.007","article-title":"Safety of nanosuspensions in drug delivery","volume":"13","author":"Wang","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0490","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40199-019-00281-4","article-title":"Intranasal zotepine nanosuspension: intended for improved brain distribution in rats","volume":"27","author":"Pailla","year":"2019","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13030391","article-title":"Aerosolized in vivo 3D localization of nose-to-brain nanocarrier delivery using multimodality neuroimaging in a rat model-protocol development","volume":"13","author":"Veronesi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0500","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.2174\/0929867326666190827151741","article-title":"Intranasal nanoparticulate systems as alternative route of drug delivery","volume":"26","author":"Alshweiat","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0505","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/pharmaceutics11020084","article-title":"Nanoemulsions for nose-to-brain drug delivery","volume":"11","author":"Bonferoni","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0510","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0515","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1208\/s12249-016-0552-9","article-title":"Quetiapine nanoemulsion for intranasal drug delivery: evaluation of brain targeting efficiency","volume":"18","author":"Boche","year":"2017","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0520","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2016.02.038","article-title":"Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies","volume":"503","author":"El-Zaafarany","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0525","first-page":"1","article-title":"Impact of ultrasonication techniques on the preparation of novel amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy","volume":"23","author":"Ahmad","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0530","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/27\/43\/435101","article-title":"Design Expert\u00ae supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson\u2019s disease","volume":"27","author":"Kumar","year":"2016","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0535","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.molliq.2018.01.123","article-title":"Optimization of rivastigmine nanoemulsion for enhanced brain delivery: in-vivo and toxicity evaluation","volume":"255","author":"Haider","year":"2018","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0540","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/02652048.2020.1756971","article-title":"Memantine nanoemulsion: a new approach to treat Alzheimer's disease","volume":"37","author":"Kaur","year":"2020","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0545","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/27\/2\/025102","article-title":"Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: Formulation, behavioural and biochemical estimation","volume":"27","author":"Pandey","year":"2016","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0550","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/10717544.2014.908980","article-title":"Microemulsion-based drug delivery system for transnasal delivery of Carbamazepine: preliminary brain-targeting study","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0555","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11095-017-2279-z","article-title":"Formulation and in-vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting","volume":"35","author":"Shah","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0560","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fbioe.2020.00389","article-title":"Potential of chitosan and its derivatives for biomedical applications in the central nervous system","volume":"8","author":"Ojeda-Hern\u00e1ndez","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0565","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.3390\/molecules20034124","article-title":"Carbopol-incorporated thermoreversible gel for intranasal drug delivery","volume":"20","author":"Balakrishnan","year":"2015","journal-title":"Molecules."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0570","article-title":"A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases","volume":"14","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0575","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/pharmaceutics13081180","article-title":"Versatile nasal application of cyclodextrins: excipients and\/or actives?","volume":"13","author":"Rassu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120182","article-title":"Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel","volume":"594","author":"Huang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0585","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2008.08.042","article-title":"In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate","volume":"365","author":"Cao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0590","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/03639040802360510","article-title":"Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir","volume":"35","author":"Alsarra","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0595","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.044","article-title":"Stimuli-responsive in situ gelling system for nose-to-brain drug delivery","volume":"327","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0600","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2015.05.021","article-title":"Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice","volume":"490","author":"Serralheiro","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0605","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/03639045.2013.789051","article-title":"Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery","volume":"40","author":"Sharma","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0610","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2478\/acph-2020-0032","article-title":"Preparation, characterization, and in vivo pharmacokinetics of thermosensitive s nasal gel of donepezil hydrochloride","volume":"70","author":"Gu","year":"2020","journal-title":"Acta Pharma."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0615","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/03639045.2016.1225754","article-title":"Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson's disease","volume":"43","author":"Rao","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0620","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10611860903386938","article-title":"Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats","volume":"18","author":"Khan","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0625","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/847547","article-title":"Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin","volume":"2014","author":"Naik","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0630","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/10717544.2013.860501","article-title":"Nasal in-situ gels for delivery of rasagiline mesylate: Improvement in bioavailability and brain localization","volume":"22","author":"Ravi","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0635","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/10717544.2013.849778","article-title":"Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation","volume":"21","author":"Galgatte","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0640","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.colsurfb.2017.08.031","article-title":"Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies","volume":"159","author":"Salatin","year":"2017","journal-title":"Colloids Surf. B."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0645","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jddst.2017.09.021","article-title":"Brain targeted rivastigmine mucoadhesive thermosensitive In situ gel: Optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution","volume":"43","author":"Abouhussein","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0650","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1208\/s12249-017-0844-8","article-title":"Development and evaluation of pH-responsive cyclodextrins based in situ gel of paliperidone for intranasal delivery","volume":"19","author":"Sherje","year":"2018","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0655","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10717544.2017.1357148","article-title":"Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation","volume":"24","author":"Fatouh","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0660","doi-asserted-by":"crossref","first-page":"107","DOI":"10.30827\/ars.v58i3.6528","article-title":"Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study","volume":"58","author":"Pathan","year":"2017","journal-title":"Ars Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0665","article-title":"Formulation and characterization of intranasal delivery of nortriptyline hydrochloride thermo reversible gelling system in treatment of depression","volume":"55","author":"Pathan","year":"2017","journal-title":"Acta Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0670","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/1061186X.2014.994097","article-title":"Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: Behavioural and biochemical assessment","volume":"23","author":"Kaur","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0675","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/bab.1917","article-title":"Synthesis and characterization of thermosensitive hydrogel based on quaternized chitosan for intranasal delivery of insulin","volume":"68","author":"Bahmanpour","year":"2021","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0680","series-title":"In Situ Hexosomal Gel as a Promising Tool to Ameliorate the Transnasal Brain Delivery of Vinpocetine: Central Composite Optimization and in Vivo Biodistribution","first-page":"2213","volume":"109","author":"Bakr","year":"2020"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119384","article-title":"Intranasal tetrandrine temperature-sensitive in situ hydrogels for the treatment of microwave-induced brain injury","volume":"583","author":"Zhang","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0690","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1039\/C9BM02006C","article-title":"Intranasal delivery of berberine via in situ thermoresponsive hydrogels with non-invasive therapy exhibits better antidepressant-like effects","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2021.12.009_bb0695","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jphp.12043","article-title":"Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel","volume":"65","author":"Chen","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0700","first-page":"1104","article-title":"Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration","volume":"41","author":"Tao","year":"2006","journal-title":"Yao Xue Xue Bao."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0705","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2006.12.029","article-title":"Huperzine A in rat plasma and CSF following intranasal administration","volume":"337","author":"Yue","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189478","article-title":"A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0715","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.colsurfb.2016.08.011","article-title":"Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery","volume":"47","author":"Hao","year":"2016","journal-title":"Colloids Surf. B."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0720","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/pharmaceutics12030251","article-title":"Pharmacotechnical development of a nasal drug delivery composite nanosystem intended for Alzheimer\u2019s disease treatment","volume":"12","author":"Adnet","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0725","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/pharmaceutics10020040","article-title":"In situ-based gels for nose to brain delivery for the treatment of neurological diseases","volume":"10","author":"Aderibigbe","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0730","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.nano.2018.10.013","article-title":"Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke","volume":"18","author":"Li","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0735","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1208\/s12249-014-0189-5","article-title":"Intranasal drug delivery of olanzapine loaded chitosan nanoparticles","volume":"15","author":"Baltzley","year":"2014","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0740","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10611860903483396","article-title":"Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses","volume":"18","author":"Al-Ghananeem","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0745","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3109\/03639045.2014.991400","article-title":"Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting","volume":"41","author":"Jafarieh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0750","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1002\/jps.24557","article-title":"Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity","volume":"104","author":"Elnaggar","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0755","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijbiomac.2016.04.076","article-title":"Application of box-behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route","volume":"89","author":"Shah","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0760","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0765","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2016.02.032","article-title":"Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration","volume":"227","author":"Van Woensel","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.10.011","article-title":"Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression","volume":"48","author":"Haque","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0775","first-page":"1955","article-title":"Gelatin nanoparticle mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0780","first-page":"72","article-title":"Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain","volume":"13","author":"Liu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0785","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11095-009-0041-x","article-title":"Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy","volume":"27","author":"Jain","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0790","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1080\/10717544.2016.1183721","article-title":"Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency","volume":"23","author":"Abd-Elal","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0795","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2217\/nnm.10.28","article-title":"Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan","volume":"5","author":"Jain","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0800","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1080\/10717544.2016.1223216","article-title":"Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: in vitro optimization, ex vivo determination of cytotoxicity, in vivo biodistribution and pharmacodynamics studies","volume":"23","author":"Nour","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0805","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.carbpol.2012.02.051","article-title":"Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation","volume":"89","author":"Haque","year":"2012","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0810","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/17425247.2019.1690452","article-title":"In vivo biodistribution of venlafaxine-PLGA nanoparticles for brain delivery: plain vs. functionalized nanoparticles","volume":"16","author":"Cayero-Otero","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0815","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jsps.2016.12.003","article-title":"Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery","volume":"25","author":"Tong","year":"2017","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0820","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0825","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jpsychires.2012.05.014","article-title":"Intranasal administration of nanostructured lipid carriers containing CNS acting drug: Pharmacodynamic studies and estimation in blood and brain","volume":"46","author":"Alam","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0830","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/10717544.2013.822945","article-title":"Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood","volume":"20","author":"Alam","year":"2013","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0835","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2014.05.004","article-title":"Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug","volume":"470","author":"Alam","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0840","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/1871524919666181126124846","article-title":"Development and characterization of nasal delivery of selegiline hydrochloride loaded nanolipid carriers for the management of parkinson's disease","volume":"19","author":"Mishra","year":"2019","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0845","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.xphs.2020.04.007","article-title":"Coated lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule","volume":"109","author":"Salem","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0850","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lfs.2016.08.033","article-title":"Development of risperidone liposomes for brain targeting through intranasal route","volume":"163","author":"Narayan","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0855","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/08982104.2012.700460","article-title":"Brain delivery of olanzapine by intranasal administration of transfersomal vesicles","volume":"22","author":"Salama","year":"2012","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0860","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3109\/10717544.2015.1120364","article-title":"Comparative study between simple and optimized liposomal dispersion of quetiapine fumarate for diffusion through nasal route","volume":"23","author":"Upadhyay","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0865","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jsps.2016.07.003","article-title":"Direct and enhanced delivery of nanoliposomes of anti-schizophrenic agent to the brain through nasal route","volume":"25","author":"Upadhyay","year":"2017","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0870","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/pharmaceutics11020064","article-title":"Formulation strategies to improve nose-to-brain delivery of donepezil","volume":"11","author":"Espinoza","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0875","first-page":"205","article-title":"Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil","volume":"10","author":"Al Asmari","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0880","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2018.11.002","article-title":"Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents","volume":"133","author":"Musumeci","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0885","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2020.119148","article-title":"Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease","volume":"579","author":"Bhattamisra","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0890","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/pharmaceutics11010026","article-title":"Fabrication optimization and evaluation of rotigotine loaded chitosan nanoparticles for nose-to-brain delivery","volume":"11","author":"Tzeyung","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0895","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1567201815666181004094707","article-title":"Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice","volume":"16","author":"Sunena","year":"2019","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0900","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","article-title":"Pharmacokinetic behaviour and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes","volume":"34","author":"Li","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0905","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13346-019-00622-5","article-title":"Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles","volume":"9","author":"Nigam","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0910","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.colsurfb.2018.11.025","article-title":"Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: Formulation design, characterization and nasal toxicity study","volume":"174","author":"Praveen","year":"2019","journal-title":"Colloids Surf. B."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","article-title":"Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity","volume":"109","author":"Raj","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0920","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","article-title":"Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting","volume":"25","author":"Chu","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0925","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1208\/s12249-015-0294-0","article-title":"Nose to brain delivery of PLGA-diazepam nanoparticles","volume":"16","author":"Sharma","year":"2015","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0930","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","article-title":"In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery","volume":"25","author":"Arisoy","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0935","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/10717544.2018.1428242","article-title":"In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates","volume":"25","author":"Giuliani","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0940","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2004.01.039","article-title":"Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain","volume":"275","author":"Zhang","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0945","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","article-title":"Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model","volume":"48","author":"Md","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0950","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","article-title":"X, Jiang, Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration","volume":"121","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0955","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jps.21939","article-title":"Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations","volume":"99","author":"Migliore","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0960","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","article-title":"Intranasal H102 peptide loaded liposomes for brain delivery to treat alzheimer\u2019s disease","volume":"32","author":"Zheng","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0965","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2019.06.021","article-title":"Nose-to-brain delivery of hyaluronate\u2013FG loop peptide conjugate for non-invasive hypoxic-ischemic encephalopathy therapy","volume":"307","author":"Kim","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-0172-y","article-title":"Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice","volume":"5","author":"Takeuchi","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0975","article-title":"Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine","volume":"582","author":"Le","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep44718","article-title":"Non-invasive aerosol delivery and transport of gold nanoparticles to the brain","volume":"7","author":"Raliya","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0985","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/MDER.S70856","article-title":"Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles","volume":"8","author":"Kanazawa","year":"2015","journal-title":"Med. Devices"},{"key":"10.1016\/j.jconrel.2021.12.009_bb0990","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijbiomac.2019.02.005","article-title":"Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery","volume":"129","author":"Piazzini","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb0995","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","article-title":"Exosomes as drug delivery vehicles for parkinson's disease therapy","volume":"207","author":"Haney","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119302","article-title":"Investigating the potential of utilizing glycerosomes as a novel vesicular platform for enhancing intranasal delivery of lacidipine","volume":"582","author":"Naguib","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1005","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S171490","article-title":"PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies","volume":"13","author":"Silva-Abreu","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jddst.2017.11.013","article-title":"Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain","volume":"43","author":"Sanchez-Ramos","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/brainsci9100275","article-title":"Neuroprotective and antioxidant effect of naringenin loaded nanoparticles for nose-to-brain delivery","volume":"9","author":"Md","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/pharmaceutics11120657","article-title":"Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders","volume":"11","author":"Cardia","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11095-019-2662-z","article-title":"Increased nose-to-brain delivery of melatonin mediated by polycaprolactone nanoparticles for the treatment of glioblastoma","volume":"36","author":"de Oliveira","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2017.11.040","article-title":"Nose-to-brain delivery of insulin enhanced by a nanogel carrier","volume":"270","author":"Picone","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2016.01.017","article-title":"Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model","volume":"224","author":"Zhao","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1040","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neuroscience.2015.07.016","article-title":"Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats","volume":"303","author":"Bender","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-017-0277-2","article-title":"Nasal delivery of nanoliposome-encapsulated ferric ammonium citrate can increase the iron content of rat brain","volume":"15","author":"Guo","year":"2017","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.colsurfb.2018.07.049","article-title":"Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model","volume":"171","author":"Pashirova","year":"2018","journal-title":"Colloids Surf. B."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/02652048.2017.1375038","article-title":"Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: formulation, characterisation and its in vivo evaluation","volume":"34","author":"Javia","year":"2017","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4155\/ppa.14.19","article-title":"Novel treatment strategies for brain tumors and metastases","volume":"3","author":"El-Habashy","year":"2014","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-modified nanocarriers for nose-to-brain delivery: From bioadhesion to targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.apsb.2016.04.001","article-title":"Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides","volume":"6","author":"Lin","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1075","doi-asserted-by":"crossref","first-page":"9888","DOI":"10.1016\/j.biomaterials.2011.09.004","article-title":"Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration","volume":"32","author":"Xia","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1080","first-page":"1","article-title":"Imaging of intranasal drug delivery to the brain","volume":"10","author":"Veronesi","year":"2020","journal-title":"Am. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1085","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1016\/j.biomaterials.2006.01.038","article-title":"Lectin-conjugated PEG\u2013PLA nanoparticles: preparation and brain delivery after intranasal administration","volume":"27","author":"Gao","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1090","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1021\/bc8002698","article-title":"Quantum dots bearing lectin-functionalized nanoparticles as a platform for in vivo brain imaging","volume":"19","author":"Gao","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1095","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s11095-011-0440-7","article-title":"Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration","volume":"28","author":"Kanazawa","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/MDER.S70856","article-title":"Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles","volume":"8","author":"Kanazawa","year":"2015","journal-title":"Med. Devices."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1105","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ijpharm.2012.07.029","article-title":"Penetrating-functionalized PEG\u2013PLA nanoparticles for brain drug delivery","volume":"436","author":"Xia","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jphp.12347","article-title":"Intranasal and intravenous administration of octa-arginine modified poly (lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide","volume":"67","author":"O\u2019Donnell","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","article-title":"Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration","volume":"151","author":"Wen","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1120","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/17425247.2018.1378642","article-title":"Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies","volume":"15","author":"Li","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1125","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.2147\/IJN.S120939","article-title":"Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment","volume":"11","author":"Bi","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/IJN.S151475","article-title":"Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS\/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects","volume":"13","author":"Yan","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1135","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","article-title":"Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson\u2019s disease","volume":"26","author":"Tang","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1140","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","article-title":"Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1145","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1150","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3390\/ijms18091985","article-title":"Lactoferrin: A natural glycoprotein involved in iron and inflammatory homeostasis","volume":"18","author":"Rosa","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.17816\/MAJ33848","article-title":"Potential role of lactoferrin in early diagnostics and treatment of parkinson disease","volume":"20","author":"Sokolov","year":"2020","journal-title":"Med. Acad. J."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1160","doi-asserted-by":"crossref","first-page":"101090","DOI":"10.1016\/j.redox.2018.101090","article-title":"Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice","volume":"21","author":"Xu","year":"2019","journal-title":"Redox Boil."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1165","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopha.2018.12.118","article-title":"A pilot study on the effect of lactoferrin on Alzheimer\u2019s disease pathological sequelae: Impact of the p-Akt\/PTEN pathway","volume":"111","author":"Mohamed","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1170","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ijbiomac.2020.07.167","article-title":"Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications","volume":"164","author":"Sabra","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1175","series-title":"Frontiers in Biomedical Devices","article-title":"Nasal spray device for administration of two-part drug formulations","volume":"41037","author":"Rautiola","year":"2019"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1180","first-page":"299","article-title":"Intranasal Drug Administration- an attractive delivery route for some drugs","author":"Marx","year":"2015","journal-title":"Drug Discov. Dev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159150","article-title":"Nasal absorption of macromolecules from powder formulations and effects of sodium carboxymethyl cellulose on their absorption","volume":"11","author":"Tanaka","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1190","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.apt.2020.03.028","article-title":"Potentials and challenges of levodopa particle formulation for treatment of Parkinson\u2019s disease through intranasal and pulmonary delivery","volume":"31","author":"Paul","year":"2020","journal-title":"Adv. Powder Technol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1195","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1021\/acs.molpharmaceut.6b00453","article-title":"Intranasal eutectic powder of zolmitriptan with enhanced bioavailability in the rat brain","volume":"13","author":"Khan","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1200","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2018.06.011","article-title":"Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery","volume":"129","author":"Salade","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/pharmaceutics12010014","article-title":"Spray dried formulations for inhalation\u2014Meaningful characterisation of powder properties","volume":"12","author":"J\u00fcptner","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4274\/tjps.galenos.2018.15870","article-title":"Deposition pattern of polydisperse dry powders in andersen cascade impactor-aerodynamic assessment for inhalation experimentally and in silico","volume":"17","author":"Dechraksa","year":"2020","journal-title":"Turkish J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1416-x","volume":"20","author":"Mitchell","year":"2019","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jconrel.2018.10.020","article-title":"Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine","volume":"292","author":"Thakkar","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1225","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/1061186X.2019.1574300","article-title":"Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer\u2019s disease","volume":"27","author":"Tiozzo","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1230","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jconrel.2018.12.050","article-title":"Dispersible hydrolytically sensitive nanoparticles for nasal delivery of thyrotropin releasing hormone (TRH)","volume":"295","author":"Zada","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1235","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/molecules25051065","article-title":"Investigation of the absorption of nanosized lamotrigine containing nasal powder via the nasal cavity","volume":"25","author":"Ambrus","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1240","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17425247.2020.1762563","article-title":"Nose-to-brain delivery of antipsychotics using nanotechnology: a review","volume":"17","author":"Tan","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1250","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.xphs.2017.08.024","article-title":"Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics","volume":"106","author":"Wavikar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1255","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1260","first-page":"2088","article-title":"Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting, Artif Cells Nanomed","volume":"46","author":"Selvaraj","year":"2018","journal-title":"Biotechnol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1265","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.xphs.2020.04.007","article-title":"Coated lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule","volume":"109","author":"Salem","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1270","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/pharmaceutics11100540","article-title":"Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives","volume":"11","author":"Hong","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1275","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pharmaceutics12070599","article-title":"Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters","volume":"12","author":"Cunha","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1280","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.apsb.2014.10.005","article-title":"Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation","volume":"4","author":"Yasir","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1285","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jsps.2016.07.003","article-title":"Sheth Direct and enhanced delivery of nanoliposomes of anti-schizophrenic agent to the brain through nasal route","volume":"25","author":"Upadhyay","year":"2017","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1295","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/nnm-2018-0289","article-title":"Asenapine maleate-loaded nanostructured lipid carriers: optimization and in vitro, ex vivo and in vivo evaluations","volume":"14","author":"Managuli","year":"2019","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1300","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1039\/C5RA19793G","article-title":"Intranasal delivery of asenapine loaded nanostructured lipid carriers: Formulation, characterization, pharmacokinetic and behavioural assessment","volume":"6","author":"Singh","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1305","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.xphs.2019.05.001","article-title":"Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: in vitro and in vivo studies","volume":"108","author":"Jazuli","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1310","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3109\/10717544.2014.885999","article-title":"Optimization of artemether-loaded NLC for intranasal delivery using central composite design","volume":"22","author":"Jain","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1315","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1320","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1039\/C5RA19113K","article-title":"Nose to brain delivery of astaxanthin-loaded solid lipid nanoparticles: fabrication, radio labeling, optimization and biological studies","volume":"6","author":"Bhatt","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1325","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146503","article-title":"Pharmacokinetics, pharmacodynamics and toxicity of Baicalin liposome on cerebral ischemia reperfusion injury rats via intranasal administration","volume":"1726","author":"Xiang","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1330","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104795","article-title":"Nose to brain drug delivery - A promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion","volume":"159","author":"Long","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1335","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","article-title":"Nose-to-brain peptide delivery - the potential of nanotechnology","volume":"26","author":"Samaridou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1340","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s10989-019-09971-8","article-title":"Intranasal drug delivery into mouse nasal mucosa and brain utilizing arginine-rich cell-penetrating peptide-mediated protein transduction","volume":"26","author":"Miwa","year":"2019","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-36210-9","article-title":"Effective nose-to-brain delivery of exendin-4 via co-administration with cell-penetrating peptides for improving progressive cognitive dysfunction","volume":"8","author":"Kamei","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1350","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1248\/yakushi.17-00138","article-title":"Nose-to-brain delivery of peptide drugs enhanced by co-administration of cell-penetrating peptides: therapeutic potential for dementia","volume":"137","author":"Kamei","year":"2017","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1355","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146673","article-title":"Insulin-like growth factor-1 inhibits spreading depression-induced trigeminal calcitonin gene related peptide, oxidative stress & neuronal activation in rat","volume":"1732","author":"Won","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1360","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2017.09.022","article-title":"Intranasally administered IGF-1 inhibits spreading depression in vivo","volume":"1677","author":"Grinberg","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1365","first-page":"512","article-title":"Semi-automatic radiolabeling of insulin-like growth factor-1 protein for the verification of its nose-to-brain delivery by positron emission tomography imaging","volume":"61","author":"Bhuyian","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1370","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnins.2019.00038","article-title":"Innovative therapy for Alzheimer's disease-with focus on biodelivery of NGF","volume":"13","author":"Mitra","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1375","first-page":"67","article-title":"Long-term non-invasive treatment via intranasal administration of nerve growth factor protects the human brain in frontotemporal dementia associated with corticobasal syndrome: a pilot study","volume":"2","author":"de Bellis","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1380","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jconrel.2020.03.027","article-title":"An in vitro and in vivo study of the brain-targeting effects of an epidermal growth factor-functionalized cholera toxin-like chimeric protein","volume":"322","author":"He","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1385","article-title":"Intranasal delivery of VEGF enhances compensatory lung growth in mice","volume":"13","author":"Dao","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-9-117","article-title":"Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the sub-ventricular zone","volume":"9","author":"Ma","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1395","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.nano.2013.10.009","article-title":"Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats","volume":"10","author":"Zhao","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1400","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2147\/NDT.S227598","article-title":"A study of antidepressant effect and mechanism on intranasal delivery of BDNF-HA2TAT\/AAV to rats with post-stroke depression","volume":"16","author":"Chen","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1405","first-page":"1","article-title":"Focused ultrasound-enhanced intranasal brain delivery of brain-derived neurotrophic factor","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1410","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnmol.2016.00108","article-title":"Non-viral nucleic acid delivery strategies to the central nervous system","volume":"9","author":"Tan","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1415","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2017.187","article-title":"Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I","volume":"28","author":"Belur","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1420","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00335-018-9772-5","article-title":"Insights into the pathogenesis of herpes simplex encephalitis from mouse models","volume":"29","author":"Mancini","year":"2018","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1425","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fneur.2017.00028","article-title":"Mesenchymal stem cells in the treatment of traumatic brain injury","volume":"8","author":"Hasan","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1430","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/NDT.S238646","article-title":"Intranasal delivery of bone marrow stromal cells preconditioned with Fasudil to treat a mouse model of parkinson's disease","volume":"16","author":"Tang","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1435","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0963689718754561","article-title":"The route by which intranasally delivered stem cells enter the central nervous system","volume":"27","author":"Galeano","year":"2018","journal-title":"Cell Transplant."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1440","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1574885512666170921145204","article-title":"Advances in drug delivery from nose to brain: an overview","volume":"13","author":"Hirlekar","year":"2018","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1445","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4155\/tde-2018-0005","article-title":"Looking to the future of nasal drug delivery\u2013an interview with Per Gisle Djupesland","volume":"9","author":"Djupesland","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1450","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective\u2014a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1455","series-title":"Nasal Delivery Devices","author":"Djupesland","year":"2015"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1460","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrneurol.2016.143","article-title":"New strategies for the treatment and prevention of primary headache disorders","volume":"12","author":"Schuster","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1465","article-title":"Development of a precision olfactory delivery (POD\u00ae)-Olanzapine drug-device product for agitation","volume":"20","author":"Satterly","year":"2019","journal-title":"West. J. Emerg. Med."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1470","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2147\/IJN.S77520","article-title":"Improving intranasal delivery of neurological nanomedicine to the olfactory region using magnetophoretic guidance of microsphere carriers","volume":"10","author":"Xi","year":"2015","journal-title":"Int. J. Nanomedicine"},{"issue":"111","key":"10.1016\/j.jconrel.2021.12.009_bb1475","first-page":"53902","article-title":"Modeling and Simulations of olfactory drug delivery with passive and active controls of nasally inhaled pharmaceutical aerosols","author":"Si","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1480","series-title":"Iontophoresis Analgesic Medications, StatPearls","author":"Sheikh","year":"2020"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1485","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1567201812666150909093050","article-title":"Design and testing of electric-guided delivery of charged particles to the olfactory region: experimental and numerical studies","volume":"13","author":"Xi","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1490","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/10611860400000938","article-title":"Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration","volume":"12","author":"Lerner","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1510","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/alr.22550","article-title":"Evaluating the readability and understandability of intranasal corticosteroid delivery instructions","volume":"10","author":"Lee","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1515","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejpb.2020.02.004","article-title":"Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats","volume":"149","author":"Inoue","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1520","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.lfs.2018.06.032","article-title":"Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer\u2019s disease","volume":"207","author":"Qian","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1525","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3389\/fmicb.2018.02685","article-title":"Comparative transcriptomic and metagenomic analyses of influenza virus-infected nasal epithelial cells from multiple individuals reveal specific nasal-initiated signatures","volume":"9","author":"Tan","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/pharmaceutics11080367","article-title":"Improved in vitro model for intranasal mucosal drug delivery: Primary olfactory and respiratory epithelial cells compared with the permanent nasal cell line RPMI 2650","volume":"11","author":"Ladel","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1535","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2015.12.046","article-title":"Nanoparticle transport across in vitro olfactory cell monolayers","volume":"499","author":"Gartziandia","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1540","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2017.07.019","article-title":"The role of mucus in cell-based models used to screen mucosal drug delivery","volume":"124","author":"Lechanteur","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1545","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2016.05.010","article-title":"Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells","volume":"11","author":"Dolberg","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1550","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ejps.2016.10.017","article-title":"Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - A platform for therapeutic delivery to mucosal sinus tissue","volume":"96","author":"Pandey","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1555","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","article-title":"How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods","volume":"561","author":"Salade","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1560","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejps.2016.04.018","article-title":"Development and application of an ex vivo fosphenytoin nasal bioconversion\/permeability evaluation method","volume":"89","author":"Viegas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1565","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/bc.bc_20_19","article-title":"Selection of preclinical models to evaluate intranasal brain cooling for acute ischemic stroke","volume":"5","author":"Chen","year":"2019","journal-title":"Brain Circ."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep31732","article-title":"Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery","volume":"6","author":"Kumar","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1575","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3233\/JAD-150307","article-title":"Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition","volume":"47","author":"Salameh","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2210-7-7","article-title":"Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa","volume":"7","author":"Sato","year":"2007","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1585","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.vaa.2017.06.003","article-title":"Intranasal fentanyl for acute severe pain episodes control in a dog","volume":"44","author":"Micieli","year":"2017","journal-title":"Vet. Anaesth. Analg."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1590","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0300985816629712","article-title":"Comparison of two US sheep scrapie isolates supports identification as separate strains","volume":"53","author":"Moore","year":"2016","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1595","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1124\/jpet.116.235192","article-title":"Intranasal opioid administration in Rhesus monkeys: PET imaging and antinociception","volume":"359","author":"Saccone","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1600","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1021\/acs.iecr.9b04885","article-title":"A computational systems approach to rational design of Nose-to-Brain delivery of biopharmaceutics","volume":"59","author":"Kiparissides","year":"2020","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1605","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2014.11.004","article-title":"Brain delivery of insulin boosted by intranasal co-administration with cell-penetrating peptides","volume":"197","author":"Kamei","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2015.01.017","article-title":"Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles","volume":"201","author":"Baba","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1615","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","article-title":"Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles","volume":"34","author":"Kanazawa","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1620","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.apsb.2016.04.001","article-title":"Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides","volume":"6","author":"Lin","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1625","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.2147\/IJN.S117210","article-title":"Getting into the brain: liposome-based strategies for effective drug delivery across the blood\u2013brain barrier","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1630","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.5b00088","article-title":"Nose-to-brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium","volume":"12","author":"Mistry","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1640","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal drug delivery-recent developments and future prospects","volume":"161","author":"Illum","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221330","article-title":"Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions","volume":"14","author":"Calmet","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1650","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.10.029","article-title":"Advanced formulations for Intranasal Delivery of Biologics. Advanced formulations for intranasal delivery of biologics","volume":"553","author":"Rohrer","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1655","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/10717544.2021.1889718","article-title":"Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)","volume":"28","author":"Wang","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1660","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijpharm.2004.09.023","article-title":"Improved paracellular uptake by the combination of different types of permeation enhancers","volume":"288","author":"Guggi","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1665","doi-asserted-by":"crossref","DOI":"10.1007\/s40268-021-00360-5","article-title":"Improvement of intranasal drug delivery with Intravail\u00ae alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system","author":"Rabinowicz","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1670","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2008.09.076","article-title":"Effect of cell-penetrating peptides on the nasal absorption of insulin","volume":"133","author":"Khafagyel","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2021.12.009_bb1675","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","article-title":"Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases","volume":"17","author":"Meredith","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1680","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejps.2017.02.032","article-title":"Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation","volume":"102","author":"Hada","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2021.12.009_bb1685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2610-y","article-title":"Mathematical modeling and simulation to investigate the CNS transport characteristics of nanoemulsion based drug delivery following intranasal administration","volume":"36","author":"Kadakia","year":"2019","journal-title":"Pharm. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100660X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592100660X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:28:34Z","timestamp":1759163314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592100660X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":334,"alternative-id":["S016836592100660X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.009","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}